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ABSTRACT The nicotinic acetylcholine receptor (AChR) is a pentameric transmembrane protein (X2P3Y8) that binds the
neurotransmitter acetylcholine (ACh) and transduces this binding into the opening of a cation selective channel. The agonist,
competitive antagonist, and snake toxin binding functions of the AChR are associated with the a subunit (Kao et al., 1984; Tzartos
and Changeux, 1984; Wilson et al., 1985; Kao and Karlin, 1986; Pederson et al., 1986). We used site-directed mutagenesis and
expression of AChR in Xenopus oocytes to identify amino acid residues critical for ligand binding and channel activation. Several
mutations in the a subunit sequence were constructed based on information from sequence homology and from previous
biochemical (Barkas et al., 1987; Dennis et al., 1988; Middleton and Cohen, 1990) and spectroscopic (Pearce and Hawrot, 1990;
Pearce et al., 1990) studies. We have identified one mutation, Tyr'90 to Phe (Y190F), that had a dramatic effect on ligand binding and
channel activation. These mutant channels required more than 50-fold higher concentrations of ACh for channel activation than did
wild type channels. This functional change is largely accounted for by a comparable shift in the agonist binding affinity, as assessed
by the ability of ACh to compete with a-bungarotoxin binding. Other mutations at nearby conserved positions of the a subunit
(H186F, P194S, Y198F) produce less dramatic changes in channel properties. Our results demonstrate that ligand binding and
channel gating are separable properties of the receptor protein, and that Tyr'9" appears to play a specific role in the receptor site for
acetylcholine.
INTRODUCTION
The at subunits of the AChR are known to contribute to
the ligand binding site of the receptor. Affinity labeling
with analogues of ACh or with other cholinergic ligands
has identified several amino acid residues in the cx
subunit near the ACh binding site. Particular attention
has been focused on the two conserved cysteines at
positions 192 and 193, and the surrounding region (Fig.
1). Peptides from this region bind a-BgTx with moderate
affinity (Wilson et al., 1985; Barkas et al., 1987; Oblas et
al. 1986). Two cholinergic affinity labels, bromoacetylcho-
line and 4-(N-maleimido)benzyltrimethylammonium io-
dide (MBTA), react with Cys"92 and Cyst93 of DTT-
treated receptor protein (Kao et al., 1984; Kao and
Karlin, 1986; Silman and Karlin, 1969). Nicotine and
p-(N,N dimethylamino)benzenediazonium fluoroborate
(DDF) react with the conserved tyrosine residues at
positions 190 and 198 (Dennis et al., 1988; Middleton
and Cohen, 1990). Lophotoxin analogue-1, a coral-
derived toxin that irreversibly blocks cholinergic ligand
binding, also reacts with tyrosine 190 (Abramson et al.,
1989).
There is, however, little information about the func-
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tional role of these and other amino acid residues in this
region. Mishina and colleagues (Mishina et al., 1985)
mutated the two conserved cysteine residues at positions
192 and 193 to serine. These mutant proteins exhibited a
10- to 30-fold reduction in binding affinity for carbamyl-
choline, consistent with a location near the binding site.
However, the mutant proteins did not function as
ligand-activated channels, leaving open the question of
how extensively the mutations disrupted the protein
structure. We have investigated the role of several other
conserved residues of the AChR a subunit in the region
surrounding positions 192 and 193. We prepared RNA
coding for AChRs mutated at a subunit positions 186
(His-*Phe), 190 (Tyr-*Phe), 194 (Pro- Ser), and 198
(Tyr--Phe), and expressed them in Xenopus oocytes to
assess the role of these residues in receptor function
(Fig. 1). These data (Tomaselli et al., 1991) and similar
data for the Torpedo receptor (O'Leary and White,
1991) have been presented in preliminary form.
EXPERIMENTAL PROCEDURES
Mutagenesis and in vitro RNA
transcription
The pSP64-based plasmids with cDNAs for the murine
(BC3H-1) a, ,B, y, and 8 subunits of the nicotinic AChR
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FIGURE 1 The amino acid sequences of a subunits from muscle and
neuronal tissue. The sequences are compared with the murine
BC3H-1 cell line nicotinic receptor sequence. Shaded areas indicate
identity of the amino acid with the corresponding residue in the
BC3H-1 sequence. The numbered residues were mutated as follows:
H186F, Y19OF, P194S, and Y198F. Abbreviations for the amino acid
residues are: A, ala; C, cys; D, asp; E, glu; F, phe; G, gly; H, his; I, ile;
K. lys; L, leu; M, met; N, asn; P, pro; Q, gln; R, arg; S, ser; T, thr; V, val;
W, trp; and Y, tyr. References for sequences: aBoulter et al., 1985;
bNoda et al., 1982; cNoda et al., 1983; dNef et al., 1988; eBaldwin et al.,
1988; fWada et al., 1988; 5Boulter et al., 1987; hBossy et al., 1988.
were generously provided by Dr. J. Boulter of the Salk
Institute. The a subunit cDNA was excised with EcoRI
and subcloned into pBluescript KS- (Stratagene, La
Jolla, CA) for oligonucleotide-directed mutagenesis.
Missense mutations were introduced using dut- and
ung- selection by the method of Kunkel (Kunkel, 1985).
The entire cDNA of the a subunit was sequenced
(Sanger et al., 1977) to confirm the nucleotide changes
and to guard against stray mutations. The EcoRI frag-
ments of the a subunit mutants were cloned back into
pSP64 for in vitro transcription.
RNAs encoding the wild type and mutant receptor
subunits were transcribed in a similar fashion. Plasmids
containing the wild type and mutant subunit cDNA were
linearized using Sca I. The linearized plasmid (2-4 ,ug)
was incubated in 10 mM NaCl, 6 mM MgCl2, 40mM Tris
(pH 7.5), 1 mM dithiothreitol, 2 mM spermidine, NTPs
(1 mM each except GTP which was 0.2 mM), 0.6 mM
diguanosine triphosphate (Pharmacia, Piscataway, NJ),
30U SP6 RNA polymerase, and 100 U RNasin (Promega,
Madison, WI) at 37° for 1 h. An additional 30 U of SP6
RNA polymerase and 100 U RNasin were added after
an hour and the incubatiorn was continued for another
hour. The template DNA was removed with 4 U of
RNase-free RQ1 DNase (Promega, Madison, WI) for 15
min at 37°. The RNA was extracted with phenolchloro-
form and chloroform, precipitated from isopropanol
then resuspended in DEPC-treated water at a concentra-
tion of - 0.2 Rg/4il. Subunit RNA was mixed in a ratio of
2a:1 3:1y:18 for later injection into oocytes.
Preparation and microinjection of
oocytes
Adult female, HCG-primed Xenopus laevis (Xenopus I,
Ann Arbor, MI) were anesthetized by immersion in
0.17% aminobenzoic acid ethyl ester and several lobes of
ovary were removed through a small abdominal incision.
Individual stage V or VI oocytes were isolated by
manual dissection followed by incubation in 0.5-2 mg/ml
collagenase (type IA; Sigma Chemical Co., St. Louis,
MO) in calcium-free saline (82 mM NaCl, 2 mM KCl, 1
mM MgCl2, 5 mM Hepes pH 7.6) for 1-2 h. The oocytes
were allowed to recover in amphibian saline (96 mM
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM
Hepes pH 7.6) before injection.
Selected oocytes were injected with 25-50 nl of RNA
solution using a positive displacement injector (Drum-
mond Instruments, Broomhall, PA) through glass bores
with tip diameters of 20-40 ,um. The injected oocytes
were incubated for at least 48 h in amphibian saline
supplemented with 100 U/ml penicillin and 100 p,g/ml
streptomycin sulfate (Gibco BRL, Gaithersburg, MD),
0.5 mM theophylline, and 2 mM Na pyruvate.
Electrophysiology
The oocytes were screened for ACh-induced current by
two microelectrode voltage clamp as previously de-
scribed (Tomaselli et al., 1990). Whole oocytes were
continuously perfused with ACh at a concentration that
elicited near maximal current response for the channel
variant being tested. Oocytes with sufficient whole cell
current (>0.5 ,uA at -30 mV holding potential) were
then patch clamped. The oocytes were devitellinized in
preparation for patch clamp recording as previously
described (Methfessel et al., 1986). Excised outside-out
patches (Hamill et al., 1981) were obtained in symmetric
pipette and bath solutions (in mM): 97 KCl, 1 MgCl2, 0.2
mM EGTA, 5 K-Hepes, pH 7.5. Patches were continu-
ously perfused and currents were elicited by the applica-
tion of the bath solution containing the desired concen-
tration of ACh.The patch was positioned in a custom-
designed bath at the convergence point of streams of
control and ACh-containing solution. Rapid solution
changes (1-2 ms) were made by computer-controlled
solenoid switches as previously described (Maconachie
and Knight, 1989). ACh was applied in 400 ms pulses
being delivered no more frequently than every 5 s.
Currents were recorded by a List EPC7 patch clamp
amplifier (List-electronic, Darmstadt, West Germany).
During pulsatile application of ACh the currents were
digitized at 2.5 kHz and filtered at 1 kHz (8-pole Bessel,
-3 dB). The level of channel activity varied from patch
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to patch; ensemble averages were compiled from 5-32
individual records. The peak of the ensemble average
current at a given ACh concentration was corrected for
ACh block using the measured single channel current.
The ensemble average currents were then normalized to
the maximal corrected current elicited from that patch
and are plotted against the log of the ACh concentra-
ti6n. The single channel current voltage relationships
were obtained by continuous application of ACh at the
desired concentration with rampwise or steady-state
voltage changes. Under these conditions the currents
were digitized at 10 kHz and filtered at 2 kHz (8-pole
Bessel, -3dB). All recordings were done at room
temperature 22-25°C.
Toxin and competition binding
Whole oocyte binding was performed on 5-20 oocytes
injected with wild type or mutant AChR channel RNA
and a similar number of naive oocytes. The cells were
incubated in (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1
MgCl2, 5 Hepes pH 7.6, 0.1% bovine serum albumin and
saturating [1"I]-a-BgTx (1,000 counts/fmol) for 2-4 h,
then washed with the same solution minus the labeled
toxin. The oocytes were counted on an LKB model 1282
gamma counter. The number of counts per oocyte were
corrected for nonspecific binding by subtracting the
average number of counts bound to uninjected oocytes.
The density of receptors in the oocyte surface mem-
brane is estimated as fmols of bound toxin per oocyte.
Membrane preparation and toxin binding assays were
performed as previously described (McLaughlin and
Hawrot, 1989). Briefly, oocyte membranes were pre-
pared fresh or in some cases from previously frozen
cells. 100-200 oocytes were homogenized in 0.1 ml/
oocyte of membrane binding buffer (in mM: 140 NaCl,
20 Na phosphate pH 7.5, 1 EDTA, 1 EGTA, 0.5
phenylmethylsulfonyl fluoride, and 200 U/ml aprotinin).
Homogenates were centrifuged for 30 min at 20,000 x g,
pellets were then resuspended in 0.04 ml/oocyte of
membrane binding buffer and stored at - 80°C.
Homogenized membranes (0.16 ml) were incubated
for 3 h at room temperature in a final volume of 0.22 ml
with 2.5 nM "2I labeled-a-BgTx and the desired concen-
tration of ACh. The samples were then diluted to 6 ml
with cold Tris-buffered saline (in mM: 150 NaCl, 50
Tris-HCl pH 7.6) and filtered through Whatman GF/F
filters and washed. The filters were counted on an LKB
model 1282 gamma counter to determine the level of
['"I]-a-BgTx bound. Correction for nonspecific binding
was made using a parallel protocol done in the presence
of 1.25 p,M unlabeled a-BgTx.
RESULTS AND DISCUSSION
Each mutant was assayed electrophysiologically to deter-
mine its functional response to ACh. Outside-out patches
from injected oocytes were placed in a stream of bathing
solution that could be switched rapidly (within 1-2 ms)
to a solution containing a known, constant concentration
ofACh. Patches from oocytes expressing the wild type or
mutant channels typically contained many channels
( - 5-50) that opened rapidly in response to ACh appli-
cation (Fig. 2). A dose-response curve for each channel
variant was made by compiling ensemble averages of the
responses to repeated presentations of each concentra-
tion studied, and measuring the peak of the current
response (Fig. 2,A and B). All of the mutant channels
respond to ACh, but the Y19OF mutant is dramatically
altered in its dose response and requires millimolar
concentrations of ACh for channel opening (Fig. 2 C;
Table 1).
This change in the sensitivity of the Y19OF mutant
could be due either to a change in the binding affinity of
the receptor for ACh or to a change in the energetics of
opening of the channel after binding. To distinguish
between these possibilities, we assessed the ACh bind-
ing affinity of the mutants by measuring the ability of
ACh to compete for [1251]-t-bungarotoxin binding. The
affinity of toxin itself is relatively unaffected by the
mutations (Table 1), but the ability of ACh to prevent
toxin binding is dramatically altered in the Y19OF
mutant. As for channel activation, the concentration of
ACh required for competition in the Y19OF mutant is
several hundred-fold higher than that for wild type (Fig.
3). Thus, the entire physiological effect of the mutation
can be explained by its effect on binding, without
postulating an effect on transduction.
Binding of ACh to the AChR has not only the
short-term consequence of opening the channel, but also
the longer-term consequence of receptor desensitiza-
tion. Desensitization reflects the closure of channels in
spite of prolonged exposure to ACh, and it is also
accompanied by an increase in ACh binding affinity
(Katz and Thesleff, 1957; Sine and Taylor, 1979; Sine
and Taylor, 1980). Two observations on the mutant
channels indicate that the Y19OF mutation affects ACh
binding to the resting and the desensitized states of the
channel in parallel. The first indication is that ACh
competition with toxin binding, which is measured in
long incubations and thus reflects binding to the desensi-
tized state, parallels the results on the rapid physiologi-
cal effects of ACh. The second indication comes from
direct observation of desensitization rates during the
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FIGURE 2 Physiological responses to a ACh. (A) Single channel current responses to the application of 1 ,uM (wild type), 10 F.M (Y198F), or 1
mM (Y19OF) ACh. Patches were held at a potential of -100 mV. These records were selected to show resolved single channel currents; most
patches contained many more channels. (B) Ensemble average currents obtained at a series of ACh concentrations for wild type (1, 2.5, 5, 10, and
50 ,uM), Y19OF (0.1, 0.5, 1, 3, and 5 mM) and Y198F (1, 10, 50, 300, and 500 F.M). The vertical position of each of the averages is indicative of the
ACh concentration that elicited that current. The vertical scale bar for each of the channel variants is 200 pA (wild type), 5 pA (Y19OF), and 80 pA
(Y198F). The horizontal scale bar represents 300 ms. (C) A plot of the normalized current corrected for ACh block against the log of the ACh
concentration. Each point represents the mean of the peak of the ensemble average current corrected for ACh block and normalized to the
maximal current elicited in that patch for wild type (0), Y19OF (0), and Y198F (v). The smooth curves are fits to the data generated as described
in Table 1. The Hill coefficients for each of the channel types were optimized and had values of 1.5 + 0.09 (wild type), 1.12 + 0.1 (Y19OF), and
1.17 + 0.09 (Y198F).
physiological exposure to ACh. Desensitization is typi-
cally faster at higher concentrations of agonist (Fig.
2 B). Desensitization of the Y19OF mutant, however,
remains slow even at concentrations that produce rapid
desensitization in the wild type channel; rapid desensiti-
zation of the Y19OF mutant occurs only at the millimolar
concentrations required for maximal activation of the
mutant. Thus, desensitization appears to be affected in
parallel with activation. This observation argues against
the proposed existence of separate ACh binding sites for
activation and desensitization (Dunn and Raftery, 1982).
The Y19OF mutant specifically affects the ligand
binding properties of the AChR, and does not affect its
open channel properties. The single-channel current
voltage relationship is unaltered in the mutant (Fig. 4A).
At high concentrations, ACh not only opens the AChR
channels, it also acts to block current through the open
channel (Sine and Steinbach, 1984). Such blockade
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TABLE 1 Affinity constants of wild type and mutant channels
Surface
Receptor binding oa-BgTx Kd EC50 IC50
finolloocyte nM pFM piM
Wild type 1.5 + 1.1 (7) 0.54 + 0.1 11.0 + 0.7 (6) 4.4 ± 2.0 (3)
H186F 1.9 ± 0.8 (5) 0.37 ± 0.1 21.8 + 1.2 (7) 3.2 ± 1.4 (3)
Y19OF 0.7 ± 0.3 (7) 0.49 ± 0.2 548 ± 52 (5) 338 ± 98 (3)
P194S 2.1 ± 1.5 (3) 0.66 ± 0.2 10.2 + 0.1 (7) 3.6 ± 1.8 (3)
Y198F 0.9 ± 0.4 (4) 0.44 ± 0.1 60.3 ± 8.1 (5) 23.8 ± 4.8 (3)
The EC50 and IC58s were estimated from a weighted least squares fit of
the mean normalized current and percent of control a-BgTx binding,
respectively, to the functionf = 1 - 1/(1 + ([ACh]/x)n), where x is the
EC50 or IC,o and n is the Hill coefficient (see Figs. 2 and 3 legend). The
normalized current and percent of control binding are determined as
described in Figs. 2 and 3, respectively. The EC50 and IC_Os are
presented as the mean and standard deviation. In parentheses are the
number of patches or membrane preparations for each channel
variant.
The affinity of the receptors for toxin is similar as illustrated by the K.s.
The Kds were determined by competition of labeled a-BgTx by
unlabeled toxin values are the mean of three determinations. The data
were normalized and fit as described for agonist competition of toxin
binding.
appears as a voltage-dependent reduction in the open
channel current at high ACh concentration. This reduc-
tion is identical in the wild type and mutant channels
(Fig. 4B).
The other mutations of conserved residues in this
region have smaller or no effect on binding and activa-
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FIGURE 4 Open channel properties of the AChR are not altered by
the mutations. (A) Representative single channel current voltage
relationships for the wild type (0, 0) and Y19OF (D, *). ACh at 100
FLM (open symbols) and 1 mM ACh (solid symbols). The conductances
in the negative voltage range for both channel variants are identical.
(B) Single channel current amplitude as a function of the ACh
concentration for all channel variants at a holding potential of - 100
mV: wild type (0), H186F (A), Y19OF (0), P194S (-), and Y198F
(V).
.0 I. ..
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FIGURE 3 Concentration dependence of ACh inhibition of steady-
state cL-BgTx binding for the wild type receptor and the mutant
receptor channels. Toxin binding at each ACh concentration was
normalized to the [1"I]-a-BgTx binding in the absence of agonist. The
normalized binding is the mean of at least three determinations at
each ACh concentration for wild type (0), H186F (E), Y19OF (0),
P194S (A), and Y198F (V). The data were fit and the IC50s were
determined as described in Table 1. Hill coefficients ranged from 0.7 to
1.3 for both wild type and mutant receptors.
tion by ACh. For each of the other mutants, the EC50s
and IC50s are within an order of magnitude of the wild
type values. The conserved proline residue at position
194 may conformationally constrain this region of the
receptor, but the absence of an effect of the P194S
mutation rules out a critical role for this residue. The
basic residue His'86 has been suggested to function in a
charge relay system essential to ligand binding (Pearce
and Hawrot, 1990; Pearce et al., 1990); however, muta-
tion of this residue to Phe produces no change in binding
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and only a small change in physiological response. Thus
it is possible to alter conserved residues in this region
without producing a nonspecific effect on binding and
activation, supporting the notion that Tyr"9 plays a
particular and important role in these processes. The
smaller but significant effect of the Y198F mutation also
implicates this residue in binding and channel activa-
tion.
Another suggestion that either Tyr"9 or Tyr'98 might
play an interesting role in ACh binding comes from
spectroscopic studies of synthetic peptides from this
region of the AChR that bind a-BgTx. The intrinsic
fluorescence spectra of the peptides suggest the pres-
ence of a negatively charged tyrosinate (phenolate) ion
at neutral pH (Pearce and Hawrot, 1990; Pearce et al.,
1990). The authors of this work have suggested that one
of these tyrosines might therefore be a good candidate
for the hypothetical "anionic subsite" of the AChR
binding site proposed to interact with the positively
charged, quaternary ammonium moiety common to
most cholinergic ligands. Is this proposal consistent with
our observation that mutation of Tyr'" to Phe (which
cannot ionize) produces a several hundred-fold shift in
ACh binding? Perhaps. One might expect at first that
removing a critical charge-charge interaction might
have an even greater effect on binding affinity. The
observed shift in the dose response corresponds to a
change in binding energy of 2-3 kcal/mol. This energy
is comparable, for example, to the coulombic interaction
energy of two point charges at a distance of 6-7 A in a
medium of dielectric constant 20. Thus the magnitude of
the effect may be consistent with the proposed model.
We attempted to test this hypothesis that Tyr"9 is the
anionic subsite of the AChR by substituting other amino
acids at this position, neutral glutamine or negatively
charged glutamate. Both of these mutations produce
shifts in the dose-response similar to that produced by
the Y19OF mutation (data not shown). It thus appears
that tyrosine is unique in its ability to promote ACh
binding at this position. This could mean that tyrosine,
because of its size, its shape, and the hydrogen-bonding
properties of its hydroxyl group, is critical for producing
the proper folding of the ACh binding pocket. Alterna-
tively, both the negative charge of the proposed tyrosi-
nate and the aromatic character of tyrosine may be
involved in the interaction between ACh and Tyr'".
Dougherty and Stauffer have suggested that aromatic
residues are especially well suited for binding with the
diffuse charge of quaternary ammonium moieties; their
host-guest experiments with aromatic macrocycles sup-
port this notion, as do the known structures of several
proteinaceous binding sites for quaternary amines
(Dougherty and Stauffer, 1990). The recent discovery of
a tyrosine residue critical for the high affinity blockade
of potassium channels by tetraethylammonium may
provide another such example (MacKinnon and Yellen,
1990).
We have observed a dramatic and specific effect of
mutations of Tyr"9 on the ACh binding and activation of
the nicotinic AChR. Much higher concentrations of
ACh are required to activate the mutant, and this
change in sensitivity can be entirely accounted for by a
change in the binding affinity of ACh. These results
suggest that Tyr"9 plays a critical role in producing the
binding pocket for ACh. Determining the exact role of
this and other residues in ACh binding will of course
require further studies using both mutagenesis and
structure determination.
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